Navigation Links
Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan
Date:3/6/2013

LONDON, March 6, 2013 /PRNewswire/ -- The stable growth of the European human growth hormone (hGH) market is attributed primarily to a decrease in the prices and an increase in the overall volumes of hGH drugs used.

No new indications for hGH therapy are likely to be approved by the European Medicines Agency (EMEA) over the next 3 to 5 years. This, paralleled by a stable patient population, has resulted in a saturated market that does not provide attractive opportunities for new entrants. Nevertheless, product differentiation based on innovative technologies will enable existing market participants to expand their share in this highly concentrated market.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), European Human Growth Hormones Market, finds that the market earned $0.99 billion in 2012 and estimates this to reach $1.22 billion in 2019. The research covers adult and paediatric segments.

"Product differentiation in the hGH market is aimed at 3 different levels; namely, drug delivery mechanisms, long-acting preparations and improved formulations, and combination therapy," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "Companies have increasingly started to focus on developing non-invasive delivery methods to improve patient compliance and reduce treatment withdrawal rates."

Such efforts are set to address the issue of reduced therapeutic efficacy due to poor patient compliance. With more than 80% of the target population for hGH being children below the age of 15 years, taking hGH injections on a daily basis is a major challenge. This has led to poor adherence and higher withdrawal rates from existing therapeutic regimes.

Entering into strategic collaborations with drug delivery companies could pave the way for product differentiation, while enabling market participants to gain a competitive advantage.

"Fostering strategic alliances with technology providers and drug delivery companies will help hGH manufacturers to develop other potential modes of drug delivery such as oral and pulmonary," concludes Chidambaram. "Such non-invasive drug delivery methods are likely to motivate improved patient compliance and treatment success rates."

If you are interested in more information on this research, please send an email to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com

European Human Growth Hormones Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan's related research services include: European Biosimilars Market, European Vaccines Market, and European Pharmaceutical and Biotech Contract Manufacturing Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabetes Research Institute Tests BioHub Mini Organ to Restore Natural Insulin Production in Type 1 Diabetes
2. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
3. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
4. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
5. SurgiCount Medical Launches New Surgical Sponge Product
6. Longitudinal Study Highlights Evolving Role of Medical Science Liaisons with Thought Leaders and Product Development
7. GPMG Product Helps Medical Device Specification Developers be FDA and ISO 13485 Compliant
8. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
9. GPMG Unveils a Quality System Product Designed for Initial Importers of Medical Devices
10. Asthmapolis Wins Bluetooth Breakthrough Product Award
11. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... ... February 21, 2020 , ... The business of healthcare management is complex. ... industry trends and ensuring patients digital and physical safety, there are many things to ... That’s why MaintenX International’s is excited to provide their insights on healthcare facility maintenance ...
(Date:2/20/2020)... Calif. (PRWEB) , ... February 20, 2020 , ... ... focused on addressing unmet needs in the field of urology, today announced that ... UroLift® Center of Excellence. The designation recognizes that Dr. Uberoi has achieved a ...
(Date:2/19/2020)... , ... February 19, 2020 , ... Aspire Regenerative, a ... partners with Cortex Wellness Pharmacy for a free weight-loss event on March 1, 2020. ... Girard Ave., #100, La Jolla, CA, 92037. , During the event, physicians and pharmacists ...
Breaking Medicine Technology:
(Date:2/15/2020)... ... February 14, 2020 , ... ... partnered with Baptist Easley Hospital , a member of Prisma Health, providing ... With PCPLUS, the world-class hospital was able to cut its monthly laundry management ...
(Date:2/14/2020)... ... February 14, 2020 , ... ScripHessco ... Care During Pregnancy. The guide breaks down the benefits of chiropractic care during ... chiropractic care during pregnancy is quite beneficial to the mother’s health. Seeing a ...
(Date:2/14/2020)... ... 14, 2020 , ... “The American Society for Dermatologic Surgery ... discoloration, and lines and wrinkles. And the treatments they are most interested in ... in February specifically to address the areas our patients are most concerned about,” ...
(Date:2/13/2020)... Va. (PRWEB) , ... February 13, 2020 , ... ... with seven locations in Northern Virginia: Arlington, Dulles-Aldie, Fair Oaks, Fairfax, Fredericksburg, Leesburg, ... announce that eight D.C.- and Virginia-based fertility specialists have been named as Top ...
(Date:2/11/2020)... ... February 11, 2020 , ... There are many reasons why Care ... the service that truly raises us above our competitors is our true Peer to ... board-certified Radiologist with years of clinical experience. We understand that it is impossible to ...
Breaking Medicine News(10 mins):